Intravenous delivery of oxygen microbubbles for the treatment of hypoxia and ards

Ended Project Grant Awarded Last action

Award ID
R43HL158362
Recipient
Awarding agency
Obligated
$611,076

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Place of performance
Minnesota, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The goal of this phase 1 project is to develop the as-O2-001 system for intravenous, gaseous oxygen microbubble delivery for treatment of hypoxia. Hypoxia is a catastrophic illness that can result from acute respiratory distress syndrome (ards), chronic obstructive pulmonary disease (copd), pulmonary fibrosis, covid-19, congestive heart failure and myocardial infarction. Current treatment options for severely affected patients include extracorporeal membrane oxygenation (ecmo) and mechanical ventilation, which are both invasive, expensive, and have iatrogenic sequalae. Agitated solutions INC. Is developing a novel, minimally invasive alternative: the as-O2-001 system delivers gaseous oxygen microbubbles into the inferior vena cava to delay or prevent mechanical ventilation or ecmo. Gaseous oxygen delivery has historically resulted in emboli formation; however, improved technology today enables the delivery of microbubbles (

Transactions

Action Obligated Date
Amendment $0
Amendment $305,538
Original award $305,538

Quick answers

Who received award R43HL158362?

R43HL158362 was awarded to Moonshot Medical LLC by National Heart Lung and Blood Institute (National Institutes of Health) on September 20, 2022.

How much is award R43HL158362 worth?

$611,076 has been obligated on R43HL158362.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login